TENX Tenax Therapeutics, Inc.
$1.60▼ -2.44%
Healthcare
Other
Volume 83.0K
Avg Volume (10D) 2.53M
Key Metrics & Fundamentals
Market Cap
$59.88M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.31 - 19.40
% vs 50 MA
-10.89%
% vs 200 MA
-84.14%
RSI-14
37.6
MACD Histogram
+0.0800
Beta (1Y vs SPY)
0.89
Free Cash Flow
-$14.15M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$18.78M
COGS
–
Operating Exp
$18.78M
Operating Income
-$18.78M
EBIT
-$18.78M
Pretax Income
-$17.80M
Net Income
-$17.80M
EPS (Diluted)
-0.35
Price & Volume History
Loading chart…
Recent News
Tenax Therapeutics (TENX) Stock Fair Value Falls After Cautious Analyst Calls On LEVEL Data
Simply Wall St. · Oct 24, 2026 9:16 PM ET
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
Insider Monkey · Sep 4, 2026 6:26 PM ET
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
GlobeNewswire · Sep 1, 2026 7:00 AM ET
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
The Fly · Aug 31, 2026 9:45 AM ET
Guggenheim Downgrades Tenax Therapeutics to Neutral From Buy
MT Newswires · Aug 31, 2026 6:29 AM ET
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
GlobeNewswire · Aug 29, 2026 8:21 AM ET
Chardan Downgrades Tenax Therapeutics to Neutral From Buy, Adjusts Price Target to $5 From $27
MT Newswires · Aug 11, 2026 11:49 AM ET
Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39
MT Newswires · Aug 11, 2026 7:18 AM ET
Tenax Therapeutics’ stock crashes on Phase III trial failure
Clinical Trials Arena · Aug 11, 2026 7:15 AM ET
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
MarketBeat · Aug 11, 2026 2:01 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See TENX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.